ASCO 2023: Head and neck highlights

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to cabozantinib alone in soft tissue sarcoma

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer

NSIA and Nigeria to improve treatment for Nigerians through the building of new cancer centres

NSIA and BVGH aim to improve patient outcomes and access to quality cancer care

Oncologic safety of breast conservation following NACT in women with locally advanced breast cancer

Maximising diagnosis of colon cancer with target screening